Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "daiichi sankyo company"

Daiichi Sankyo to present phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody drug conjugate at ESMO 2016 congress

Daiichi Sankyo Company, Limited announced that safety and preliminary efficacy phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody drug conjugate, will be presented during a late-breaking poster discussion session during the European ...
 PharmaBiz9 hours ago Daiichi Sankyo To Present At Late-Breaking Clinical Data For Novel HER2-Targeting Antibody Drug Conjugate In T-DM1 Pre-Treated Breast Cancer  BioSpace1 day ago Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer  International Business Times2 days ago DAIICHI SANKYO : to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer  4 Traders1 day ago
[x]  

Exelixis' collaborator Daiichi Sankyo begins phase 3 trial to evaluate CS-3150 to treat hypertension

Exelixis, Inc., a biopharmaceutical company, announced that its partner Daiichi Sankyo Company, Limited has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone (r-INN)), an oral, non-steroidal, selective mineralocorticoid receptor ...
 PharmaBiz2 days ago Exelixis Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist  Business Wire3 days ago DAIICHI SANKYO : Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid Receptor Antagonist for Treatment of Essential Hypertension  4 Traders2 days ago Daiichi Sankyo Announces New Global Head of Development  Pharmacy Choice6 days ago
[x]  

Daiichi Sankyo seeks Japanese approval for additional indication of denosumab to treat RA

Daiichi Sankyo Company, Limited announced that it has applied for additional indication of denosumab (product name: Pralia subcutaneous injection 60mg syringe) for rheumatoid arthritis-related treatment. Denosumab is the first fully human ...
 PharmaBiz5 days ago Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab  FirstWord Pharma6 days ago
PharmaVOICE

Daiichi Sankyo phase 3b ENSURE-AF study of once-daily Lixiana in patients with AF undergoing cardioversion meets primary endpoints

Daiichi Sankyo Company, Limited announced results from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm). The ...
 PharmaBiz4 weeks ago Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group  PharmaVOICE1 month ago Daiichi Sankyo Adds Leigh Ann Errico as VP of Human Resources  Citybizlist1 month ago Daiichi Sankyo Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President  FirstWord Pharma1 month ago
[x]  

ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-​Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

/PRNewswire/ -- Not for US or UK media ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion ENSURE-AF is a Prospective, ...
 Ariva.de4 weeks ago DAIICHI SANKYO : Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg  4 Traders1 month ago DAIICHI SANKYO : ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion  4 Traders4 weeks ago Daiichi Sankyo's long-acting neuraminidase inhibitor, Inavir dry powder inhaler 20mg receives Japanese additional dosage regimen approval  PharmaBiz1 month ago
[x]  

Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

Zymeworks Inc., a clinical-stage biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics including bi-specific antibodies and drug conjugates for the treatment of cancer, and Daiichi Sankyo ...
 Minyanville1 day ago
[x]  
Freshnews.com

Daiichi moves TMFs, other R&D documents onto Veeva cloud platform

Daiichi Sankyo has struck a deal to use Veeva Systems ($VEEV) cloud platform to store its R&D files. The agreement sees Daiichi use Veeva Vault to manage electronic trial master files (eTMFs), quality compliance documents and the submission assembly ...
 FierceBiotech1 month ago Daiichi Sankyo Selects Vault To Streamline Submissions, eTMF, And Quality Management  BioSpace1 month ago Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management  SPi World News1 month ago Daiichi Sankyo chooses Veeva Vault to streamline submissions, eTMF, and quality management  Pharmaceutical Business Review1 month ago
[x]  

Daiichi Sankyo Bolsters Executive Team

Daiichi Sankyohas appointed Leigh Ann Errico as the company's vice president of human resources for the U.S. administrative and commercial group. Ms. Errico brings extensive experience in change management, organizational and executive development, ...
 Contract Pharma1 month ago
Business Standard India

Hold Daiichi for contempt of court responsible for leak: RH Holdings

MUMBAI: RH Holdings, the firm owned by former Ranbaxy promoter Malvinder Singh, has said the Diiachi Sankyo should be held for contempt of court for leaking the confidential documents of the Singapore Tribunal Board (STB). The company's statement ...
 Economic Times1 month ago Daiichi award can't be enforced in India: Ex-Ranbaxy promoters  Economic Times1 month ago Daiichi case: Former Ranbaxy promoters object to enforcement of Singapore arbitration award in India  Smart Investor1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo company
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less